MRNA Drops on Positive COVID-19 Pill Test Results


During the last session 34M of Moderna, Inc.’s (NasdaqGS:MRNA) shares were traded. The stock closed at $341.09 per share indicating that it lost -$43.77 or -11.37% during that day which brings the Moderna, Inc.’s valuation to $136.96B.

The 52-week high for the Moderna, Inc.’s shares is $497.49. That puts it -31.44% from that peak but still a massive gain since the share price dropped to a 52-week low of $65.49, while the S&P 500’s share price change was of 33%.

The company currently has a 228.61 P/E ratio and a price target of $349.33.

What does the trading volume tell us about the MRNA stock?

During the last trading session, Moderna, Inc. (NasdaqGS:MRNA) has seen decay in its daily volume. The daily volume was of 19M, while in the last 10 days the average was 11.7M and last three months – 18.69M.
The decreasing interest in the MRNA stock from the investors is helping to drive the stock price down.

Growing short interest

The Moderna, Inc.’s shares are seeing an increasing short interest compared to the previous month. As of today, there are 18.81M shares being shorted which translates into 0.97 of a short ratio for MRNA, while in the previous month the shorted shares were 12.46M.

Moderna, Inc. (NasdaqGS:MRNA)’s financials

With a market cap of 136.96B, Moderna, Inc. holds a total cash of $7.99B that translates into $19.8 per share, while the total debt is of $603M.

The company has seen a decrease in the revenue with a year-over-year quarterly revenue growth percentage of 6,398.50%. The current revenue is of $7.02B that is $17.62 per share.

This is a not so good sign for the future.